Teva insider Eric Hughes sells 92,039 shares

Teva Pharmaceutical Industries Limited reports Form 144 sale notices for insider Eric Hughes.

Accepted by SEC EDGAR 03/05/2026 - 05:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited reports Form 144 sale notices for insider Eric Hughes. The filing lists two transactions: 80,762 ordinary shares sold on 03/03/2026 for $2,613,450.24 and 11,277 ordinary shares sold on 03/04/2026 for $366,102.17. The filing also references 19,654 restricted share units vesting on 03/05/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions does TEVA's Form 144 show?

The Form 144 shows insider Eric Hughes sold 80,762 shares on 03/03/2026 and 11,277 shares on 03/04/2026, with proceeds of $2,613,450.24 and $366,102.17, respectively.

Does the filing show any equity vesting for TEVA insiders?

Yes. The filing references a restricted share unit award vesting event for 19,654 ordinary shares on 03/05/2026, listed under compensation-related securities in the Form 144 excerpt.

Who is the reporting person on the TEVA Form 144?

The reporting person named is Eric Hughes, with an address listed in Tel Aviv. The Form 144 entries attribute the two sales and the associated proceeds to him in the provided excerpt.

What proceeds are reported from the TEVA share sales?

The excerpt reports total proceeds of $2,613,450.24 for 80,762 shares on 03/03/2026 and $366,102.17 for 11,277 shares on 03/04/2026, as listed in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001938678
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Hughes Eric A
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	9533	301894.86	1149812898	03/05/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/05/2025	RESTRICTED SHARE UNIT AWARD VESTING EM	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			19654	03/05/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ERIC HUGHES 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/03/2026	80762	2613450.24
ERIC HUGHES 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/04/2026	11277	366102.17

144: Remarks and Signature

Remarks	SECTION 3 E BASED ON ORDINARY SHARES. SALES WERE PERFORMED UNDER AN ESTABLISHED 10B51 PLAN ADOPTED NOVEMBER 2025
Date of Notice	03/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)